Welcome to our dedicated page for Charles Riv Labs Intl SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Charles River Laboratories disclosures can feel like running a full toxicology study鈥攄ense tables on research models, acquisition earn-outs, and animal welfare compliance stretch across hundreds of pages. If you have ever wondered, 鈥淲here can I see Charles River Laboratories insider trading Form 4 transactions before the market reacts?鈥� you are not alone.
Stock Titan鈥檚 AI turns that complexity into clarity. Our engine delivers Charles River Laboratories SEC filings explained simply, flagging what moves the needle in real time. Whether it鈥檚 a Charles River Laboratories quarterly earnings report 10-Q filing or an 8-K on a sudden facility shutdown, you receive instant context alongside the source document.
- 10-K & 10-Q 鈥� Backlog trends, segment margins, and R&D spend with Charles River Laboratories earnings report filing analysis.
- Form 4 鈥� Track Charles River Laboratories Form 4 insider transactions real-time to spot management鈥檚 conviction.
- Proxy (DEF 14A) 鈥� Quickly surface Charles River Laboratories proxy statement executive compensation details without scrolling through legal prose.
- 8-K 鈥� Material events such as contract wins or biosecurity updates are offered as Charles River Laboratories 8-K material events explained.
Every filing arrives within minutes of hitting EDGAR, paired with AI-powered summaries, keyword search, and historical comparisons. Use cases span monitoring Charles River Laboratories executive stock transactions Form 4, evaluating acquisition synergies, or simply understanding Charles River Laboratories SEC documents with AI. Stop wading through PDF labyrinths; start focusing on decisions that matter.
Charles River Laboratories (CRL) Form 144 shows a proposed sale of 400 shares of common stock to be executed through UBS Financial Services on 08/22/2025 with an indicated aggregate market value of $61,000. The securities were originally acquired on 01/27/2023 as Performance Stock Units from Charles River Laboratories, with 8,379 units reported as acquired and payment in cash on 05/13/2025. The filer also reported two recent sales in August 2025: 800 shares sold on 08/18/2025 for $126,054 and 400 shares sold on 08/08/2025 for $5,991. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Joseph W. LaPlume, an officer and director at Charles River Laboratories (CRL) serving as EVP, Corporate Strategy & Development, reported an open-market sale of 800 shares of CRL common stock on 08/18/2025 at a reported price of $157.60 per share. After the transaction he beneficially owned 24,116 shares. The Form 4 was signed on 08/20/2025. The filing discloses a single non-derivative sale and no derivatives or additional transactions.
Charles River Laboratories (CRL) Form 144 discloses a proposed sale of 22,500 shares of common stock through Merrill Lynch on or about 08/18/2025 with an aggregate market value of $3,420,000. The notice identifies the seller as Richard Wallman and shows prior acquisitions by the seller including RSU vesting from 2017鈥�2019 and multiple open-market purchases in June鈥揓uly 2025 totaling 15,000 shares. The filing also reports recent sales by the same person in the past three months: 4,000 shares on 06/23/2025 for $550,000 and 8,500 shares on 07/21/2025 for $1,275,000. The filer certifies no undisclosed material adverse information.
Form 144 notice for Charles River Laboratories (CRL) discloses a proposed sale of 800 shares of common stock through UBS Financial Services (Weehawken, NJ) with an aggregate market value of $125,600. The shares represent part of outstanding common stock of 49,120,000 and an approximate sale date of 08/18/2025 on the NYSE. The filing shows the shares were acquired as Performance Stock Units on 01/27/2023 from Charles River Laboratories and that payment at sale is expected in cash. The filer previously sold 400 shares on 08/07/2025 for $59,991. The notice includes the customary attestation that the seller is unaware of undisclosed material adverse information.
Nomura Holdings, Inc. reports beneficial ownership of 2,681,669 shares of Charles River Laboratories common stock, representing 5.4% of the outstanding class. The total includes 473,087 shares held by Nomura Global Financial Products, Inc. (NGFP), 1,096,182 shares held by Nomura Securities International, Inc. (NSI), and call options exercisable within 60 days covering 1,112,400 shares (1,100,000 by NGFP and 12,400 by NSI). The percent is calculated using 49,209,000 shares outstanding as of June 28, 2025, per the issuer's quarterly report. The filing states these holdings were acquired and are held in the ordinary course of business.
Charles River Laboratories EVP Joseph W. LaPlume reported a sale of 400 shares of common stock on 08/07/2025 at $150.04 per share. After the transaction he directly owned 24,916 shares. The filing is a routine Form 4 disclosure recording an officer's change in beneficial ownership and shows no derivative transactions.
FAQ
What is the current stock price of Charles Riv Labs Intl (CRL)?
What is the market cap of Charles Riv Labs Intl (CRL)?
